Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations
Andrew M. Brunner(Harvard University), Amir T. Fathi(University of Southern California), Hua Yang(China Pharmaceutical University), Seth A. Wander(Harvard University), Meghan Burke(Harvard University), Yi‐Bin Chen(Massachusetts General Hospital), Hossein Sadrzadeh(Boston University), Karen K. Ballen(University of Virginia Health System), Kimberly Straley(Agios Pharmaceuticals (United States)), Katharine Yen(Agios Pharmaceuticals (United States)), A. John Iafrate(Massachusetts General Hospital), Sophia Adamia(Beth Israel Deaconess Medical Center), Sam Agresta(Agios Pharmaceuticals (United States)), Richard M. Stone(Dana-Farber Cancer Institute), Ashley Perry(Harvard University), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), Donna Neuberg(Otsuka (Japan)), Regina Silver(Harvard University), Philip C. Amrein(Massachusetts General Hospital)
Cited by 1
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k